Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies 13/09/2018 by Intellectual Property Watch 6 Comments Marcela Fogaça Vieira and Pedro Villardi write: The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment was set for 6 September. The cancellation occurred on the eve of the judgment, something very rare in the practice of the Court. The lack of decision on the case only benefits the transnational companies awarded with hundreds of undue monopolies. Just a few days before, the President of the STF – Judge Carmem Lucia – had a meeting with Interfarma, the association of multinational pharmaceutical companies in Brazil.
Civil Society Pushes EPO To Invalidate Hepatitis C Patent 12/09/2018 by Catherine Saez, Intellectual Property Watch 1 Comment The European Patent Office is expected to hold oral proceedings later this week on a challenge filed against a Gilead patent on hepatitis C treatment. Invalidation of the patent would open the way to competition and lower prices, according to civil society groups which initiated the challenge. But according to an EPO source, the company is seeking at most an amendment to the patent.
Extended Monopolies On Biologic Drugs – A Warning To Developing Countries 10/09/2018 by Intellectual Property Watch Leave a Comment Historically, the US has been the primary demandeur of maximalist IP norms in FTAs. Pharmaceutical IP is market-driven, and this is no different for biologic drugs, which dominate the list of bestselling drugs worldwide, making them important economic commodities. Developing country governments must take note of the US pushing for biologics exclusivity through NAFTA as this signifies an effort to change norms worldwide.
Study: Generic Drug Industry Embraces Faster, Cheaper Pathway For Challenging Patents 06/09/2018 by William New, Intellectual Property Watch 1 Comment A new study by researchers at the Program On Regulation, Therapeutics, And Law (PORTAL) at Harvard Medical School and Brigham & Women’s Hospital reveals that generic drug companies have been successful about 50% of the time when challenging patents covering FDA-approved pharmaceutical products via a new, administrative review procedure of patent validity created by Congress called “inter partes review.”
New Confidential Text Shows Draft Deal On UN Tuberculosis Declaration 05/09/2018 by David Branigan, Intellectual Property Watch 3 Comments A newly agreed draft text of the United Nations political declaration on tuberculosis was released to governments today, affirming the use of flexibilities in international trade rules on intellectual property, but excluding actionable language on those rules.
Negotiators On UN TB Resolution May Have A Deal 23/08/2018 by William New and David Branigan, Intellectual Property Watch 23 Comments NEW YORK – Negotiators for a United Nations declaration on tuberculosis, meeting intensively in New York this week, may have reached agreement today on a key sticking point related to intellectual property, innovation and access to new medicines, according to sources. An agreement, if accepted by other delegations, could allow the text to proceed to the high-profile High-Level Meeting scheduled to take place at the UN General Assembly next month.
Wearable Tech: Intellectual Property Opportunities, Risks 23/08/2018 by David Branigan, Intellectual Property Watch Leave a Comment In wearable technology, product development converges with information and communication technology, presenting new opportunities for patents, as well as new risks, according to legal experts.
Can A Surge In Activism Defeat American Big Pharma? 22/08/2018 by Guest contributor for Intellectual Property Watch Leave a Comment By Vinayak Bhardwaj – Not a day passes in America without news of a drug company raising prices on prescription drugs. Americans pay two to six times more for prescription drugs than those living in other developed countries, who earn the same income.
New EPO Chief Outlines Priorities With Global Focus; Staff Wary But Hopeful 30/07/2018 by Dugie Standeford for Intellectual Property Watch Leave a Comment Antonio Campinos, whose term as president of the European Patent Office began on 1 July, has said he wants to focus on the effectiveness of the organisation, greater global cooperation and “staff engagement.”
Negotiations On UN Tuberculosis Declaration Still Open, Reports Say 27/07/2018 by William New, Intellectual Property Watch 2 Comments Negotiations for a United Nations declaration on ending tuberculosis had drawn to a close earlier this week, with the United States seeming to succeed on a hardline position to keep mention of intellectual property rights and affordability of medicines out of the text. But nongovernmental reports say the draft has not been accepted by all members and that negotiations will have to be reopened.